| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4,428.0 | 4,100.0 |
| Profit before tax | 386.0 | 408.0 |
| Net income | 350.0 | 331.0 |
| EPS (diluted, $ a share) | $2.10 | $1.93 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +5.7% |
|---|---|
| Revenue, year on year | +8.0% |
| Operating margin | 12.9% |
10-Q filed with the SEC, NYSE: IQV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Iqvia Holdings Inc.: key numbers
- Share price
- $264.73Close, Nov 16
- Market cap
- $43.6B
- Shares outstanding
- 164.8MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iqvia Holdings Inc.
All →Iqvia Holdings Insider Eric Sherbet Sells $1.24M of Stock
Eric Sherbet sold 4,446 shares of Iqvia Holdings Inc. at $278.83 a share, worth $1.24M in total on Nov 9, 2026. Shares held after the trade: 24,989 (-15.1%).
- Value
- $1.24M
- Shares
- 4,446
- Price
- $278.83
- Holding change
- -15.1%
- Trade date
- Nov 9, 2026
Iqvia Holdings Financial Results
IQVIA reported third-quarter 2026 revenue of $4.43 billion, up 8.0% year-over-year, driven by strong growth in R&D Solutions and Commercial Solutions. The company achieved record clinical bookings of $3.2 billion and raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS.
“IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations. Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable.”
Ari Bousbib, chairman and CEO of IQVIA
Iqvia Holdings $2B Debt Financing with U.S. Bank Trust Company, National Association
IQVIA Inc., a subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2.0 billion in 6.375% senior notes due 2034. The proceeds will be used to redeem existing 5.000% notes due 2026, repay revolving credit facility debt, and cover offering expenses.
- Value
- $2B
- Counterparty
- U.S. Bank Trust Company, National Association
- Term
- through March 2034